Partnering - Out-Licensing Strategy

Sareum is an drug discovery company focused on producing targeted small molecule therapeutics to address unmet medical needs in cancer and auto-immune disease.

Sareum's strategy is to partner early stage programmes with organisations that have significant disease biology and clinical development capabilities.

We have a flexible approach to parterning, and propose several options for constructing a deal:

Sponsored research whereby Sareum research costs are covered in exchange for programme ownership. The parties jointly out-license at a pre-agreed point
Research collaboration with a major partner on a jointly nominated target. The partner supports research costs of project and has first option to license the programme at a pre-agreed point
Straight license deal of a Sareum wholly owned programme at a pre-defined stage of development, e.g. Preclinical candidate nomination

If you are interested in any of Sareum’s research programmes please contact us at:

BD@sareum.co.uk

Further information is avaialable on each or our programmes:

Chk-1 (download pdf) Aurora+FLT3&ALK (download pdf) VEGFR-3 (download pdf)

FLT3 (download pdf) TYK2 (download pdf)